Drug Trial Radar · NCT06677255
A Phase I/II Trial of VUM02 Injection for Steroid-refractory Acute Graft-versus-host Disease (SR-aGvHD) Treatment
Last checked: Nov 19, 2026Latest source record: Nov 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
149
Planned (sponsor's estimate)
Start
Jan 2025
Primary completion
Dec 2026
Study completion Dec 2028
Sponsor
- Lead sponsor
- Wuhan Optics Valley Vcanbiopharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 6, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 14 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
It is a phase I/II clinical study to evaluate the safety, tolerability and preliminary efficacy of VUM02 Injection in patients with acute graft-versus-host disease (aGvHD) who have failed systemic steroid therapy. VUM02 Injection (human umbilical cord-derived mesenchymal stromal /stem cells, hUC-MSC) is an off-the-shelf allogeneic cell therapy product comprising culture-expanded mesenchymal stromal /stem cells derived from the human umbilical cord tissue. The product is cryopreserved with the cell concentration of 5 x 10\^6 cells/mL. Patients with grade II to IV aGvHD who have failed systemic steroid therapy (i.e. patients with steroid-refractory aGvHD (SR-aGvHD)), will be recruited into this study. This study consists of two phases, a dose-escalation phase (phase I) and a dose-expansion phase (phase II).
Conditions
- Steroid-refractory Acute Graft-versus-host Disease
Interventions
VUM02 Injection (UC-MSCs)+BATDrug
The dose-escalation phase (phase I): Single dose escalation Phase 1a study: 3 dose levels of a single IV infusion; Multiple dose escalation Phase 1b study: 3 dose levels of twice weekly for 4 consecutive week. The dose-expansion phase (phase II): -Two dose groups will be selected by the investigator and the sponsor based on the results of the Phase 1b study, twice a week for 4 consecutive weeks for a total of 8 doses.
The control group with Best Available Therapy (BAT)Other
According to BAT scheme, the drug administration is determined by PI according to the condition of the patients.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of Dose-limiting toxicity (DLT) events (in Phase Ia and Ib )Time frame: 14 days, 28 days after the last dosing
- Overall response rate (ORR) at day 28 post initiation of therapy (in Phase II)Time frame: 28 days after the first dosing
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.